Cargando…
Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6–17 Years
The attenuated recombinant Vibrio cholerae O1 vaccine strain CVD 103-HgR, redeveloped as PXVX0200, elicits a rapid serum vibriocidal antibody (SVA) response and protects against cholera-induced diarrhea in adult volunteer challenge trials but has not been studied in children in developed countries....
Autores principales: | McCarty, James M., Gierman, Emma C., Bedell, Lisa, Lock, Michael D., Bennett, Sean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947768/ https://www.ncbi.nlm.nih.gov/pubmed/31769402 http://dx.doi.org/10.4269/ajtmh.19-0241 |
Ejemplares similares
-
Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
por: McCarty, James M., et al.
Publicado: (2021) -
Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2–5 Years in the United States
por: McCarty, James M., et al.
Publicado: (2021) -
CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe
por: Duffin, R. Paul, et al.
Publicado: (2021) -
Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR
por: Muhsen, Khitam, et al.
Publicado: (2014) -
Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults
por: Muhsen, Khitam, et al.
Publicado: (2020)